WVE
Price:
$13.79
Market Cap:
$2.14B
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a ...[Read more]
Industry
Biotechnology
IPO Date
2015-11-11
Stock Exchange
NASDAQ
Ticker
WVE
According to Wave Life Sciences Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -24.19. This represents a change of -11014.35% compared to the average of 0.22 of the last 4 quarters.
The mean historical PE Ratio of Wave Life Sciences Ltd. over the last ten years is -11.86. The current -24.19 PE Ratio has changed 20.30% with respect to the historical average. Over the past ten years (40 quarters), WVE's PE Ratio was at its highest in in the June 2022 quarter at 435.60. The PE Ratio was at its lowest in in the September 2014 quarter at -61.43.
Average
-11.86
Median
-8.51
Minimum
-64.05
Maximum
-1.33
Discovering the peaks and valleys of Wave Life Sciences Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 173.11%
Maximum Annual PE Ratio = -1.33
Minimum Annual Increase = -86.38%
Minimum Annual PE Ratio = -64.05
Year | PE Ratio | Change |
---|---|---|
2023 | -9.32 | 173.11% |
2022 | -3.41 | 156.24% |
2021 | -1.33 | -35.36% |
2020 | -2.06 | 36.10% |
2019 | -1.51 | -81.78% |
2018 | -8.30 | -8.95% |
2017 | -9.12 | -15.25% |
2016 | -10.76 | 23.37% |
2015 | -8.72 | -86.38% |
2014 | -64.05 | -36.55% |
The current PE Ratio of Wave Life Sciences Ltd. (WVE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.69
5-year avg
-3.53
10-year avg
-11.86
Wave Life Sciences Ltd.’s PE Ratio is less than Arrowhead Pharmaceuticals, Inc. (-4.63), less than CytomX Therapeutics, Inc. (7.73), less than Assembly Biosciences, Inc. (-2.10), less than Neoleukin Therapeutics, Inc. (-0.98), less than VectivBio Holding AG (-7.94), less than Icosavax, Inc. (-8.27), less than Apellis Pharmaceuticals, Inc. (-10.63), less than iTeos Therapeutics, Inc. (-3.29), less than TScan Therapeutics, Inc. (-5.52), less than ProQR Therapeutics N.V. (-12.70), greater than Alnylam Pharmaceuticals, Inc. (-104.47), greater than Blueprint Medicines Corporation (-45.48), less than Terns Pharmaceuticals, Inc. (-5.51), less than Amylyx Pharmaceuticals, Inc. (-2.34), less than Acumen Pharmaceuticals, Inc. (-2.73), less than Inozyme Pharma, Inc. (-3.09), less than X4 Pharmaceuticals, Inc. (6.04), less than Day One Biopharmaceuticals, Inc. (-17.12), less than Mereo BioPharma Group plc (-16.88),
Company | PE Ratio | Market cap |
---|---|---|
-4.63 | $2.49B | |
7.73 | $78.90M | |
-2.10 | $107.75M | |
-0.98 | $8.20M | |
-7.94 | $1.06B | |
-8.27 | $769.04M | |
-10.63 | $3.48B | |
-3.29 | $327.60M | |
-5.52 | $268.04M | |
-12.70 | $374.63M | |
-104.47 | $34.82B | |
-45.48 | $5.84B | |
-5.51 | $599.50M | |
-2.34 | $388.07M | |
-2.73 | $177.24M | |
-3.09 | $277.29M | |
6.04 | $89.59M | |
-17.12 | $1.49B | |
-16.88 | $616.59M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Wave Life Sciences Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Wave Life Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Wave Life Sciences Ltd.'s PE Ratio?
How is the PE Ratio calculated for Wave Life Sciences Ltd. (WVE)?
What is the highest PE Ratio for Wave Life Sciences Ltd. (WVE)?
What is the 3-year average PE Ratio for Wave Life Sciences Ltd. (WVE)?
What is the 5-year average PE Ratio for Wave Life Sciences Ltd. (WVE)?
How does the current PE Ratio for Wave Life Sciences Ltd. (WVE) compare to its historical average?